CHALLENGES IN CANCER THERAPY
PANCREATIC CANCER PROGNOSES
8%
survival rate within 5 years
Pancreatic cancer is one of the most lethal diseases with a 5-year survival rate of 8%. The 10-year survival rate sits at 1%.
85%
of patients are diagnosed too late
85% of pancreatic cancer patients are diagnosed at the point when tumors are not surgically resectable. This leaves chemotherapy and radiotherapy as their only treatment options with generally poor health outcomes.
0.01%
drug molecules retained in tumors
Solid tumors have considerable barriers that result in less than 0.01% delivered drug molecules retainment.
OUR SOLUTIONS
OVERALL GOAL
We have ambitions to develop a novel targeted drug delivery platform via nanoparticles to overcome drug delivery barriers in various human cancers and other non-oncological diseases.
SHORT GOAL #1
Our first step is developing targeted stroma-breaking hyaluronic acid nanoparticle drug (MIGRA-NP01) primarily focused on drug resistant pancreatic cancer.
SHORT GOAL #2
An additional goal is developing targeted stroma-breaking co-delivery approaches for enhancement of therapeutic efficacy of chemotherapeutic drugs, small molecular drugs, and immunotherapeutic agents.
